- Home
- CNTA vs MESO Comparison
CNTA vs MESO Comparison
Compare CNTA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- MESO
- Stock Information
- Founded
- CNTA 2020
- MESO 2004
- Country
- CNTA United Kingdom
- MESO Australia
- Employees
- CNTA 86
- MESO N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNTA Health Care
- MESO Health Care
- Exchange
- CNTA Nasdaq
- MESO Nasdaq
- Market Cap
- CNTA 1.6B
- MESO 1.4B
- IPO Year
- CNTA 2021
- MESO N/A
- Fundamental
- Price
- CNTA $12.43
- MESO $10.44
- Analyst Decision
- CNTA Strong Buy
- MESO Buy
- Analyst Count
- CNTA 11
- MESO 4
- Target Price
- CNTA $27.00
- MESO $18.00
- AVG Volume (30 Days)
- CNTA 1.2M
- MESO 191.2K
- Earning Date
- CNTA 08-12-2025
- MESO 02-26-2025
- Dividend Yield
- CNTA N/A
- MESO N/A
- EPS Growth
- CNTA N/A
- MESO N/A
- EPS
- CNTA N/A
- MESO N/A
- Revenue
- CNTA $15,000,000.00
- MESO $5,670,000.00
- Revenue This Year
- CNTA N/A
- MESO $178.09
- Revenue Next Year
- CNTA N/A
- MESO $305.06
- P/E Ratio
- CNTA N/A
- MESO N/A
- Revenue Growth
- CNTA 118.88
- MESO N/A
- 52 Week Low
- CNTA $8.46
- MESO $5.78
- 52 Week High
- CNTA $19.09
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- CNTA 47.36
- MESO 40.14
- Support Level
- CNTA $11.77
- MESO $11.70
- Resistance Level
- CNTA $13.06
- MESO $12.37
- Average True Range (ATR)
- CNTA 0.70
- MESO 0.44
- MACD
- CNTA 0.03
- MESO -0.04
- Stochastic Oscillator
- CNTA 51.21
- MESO 6.88
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.